Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Caught in the Middle: Chinese Biotech Firms’ Divergent Responses to U.S. Sanctions
12+ min ago (391+ words) Chinese biotech companies have been on the receiving end of U.S. economic coercion. Yet their responses have differed significantly because firm and state interests are not uniformly aligned. For Washington, treating all Chinese tech firms the same, irrespective of their actual…...
RXRX Stock Tightens Spend As AI Drug Platform Advances
49+ min ago (423+ words) Recursion Pharmaceuticals Inc. stocks have been trading up by 7.61 percent after transformative AI-driven drug discovery partnership headlines boosted optimism. RXRX has been grinding higher, not exploding. Over the last few weeks, Recursion Pharmaceuticals stock has climbed from the low $3.00 area…...
Gulf Blue Navigator Named One of America’s Best Incubators & Accelerators by TIME
2+ hour, 25+ min ago (67+ words) The University of Southern Mississippi Gulf Blue Navigator Named One of America’s Best Incubators & Accelerators by TIME Wed, 08/19/2026 - 09:13am | By: Gabriela Shinskie Gulf Blue Navigator has been recognized by TIME and Statista as one of America’s Best Incubators & Accelerators 2026, placing the…...
BioMarin Inks $490M Deal to Buy Rare Bone Disease Treatment
2+ hour, 45+ min ago (554+ words) BioMarin Pharmaceutical BMRN announced that it has entered into a definitive agreement to acquire clinical-stage biotech Alesta Therapeutics for up to $490 million. This includes an upfront payment of $275 million and the remaining $215 million in development and regulatory milestone payments. Immediately…...
NeoImmuntech has transferred U.S. and European rights to some indications of its immunotherapy candi.. - MK
7+ hour, 19+ min ago (446+ words) NeoImmuntech has transferred U.S. and European rights to some indications of its immunotherapy candidate "NT-I7" to U.S. bio companies. With up to $260 million (about 366.9 billion won), NeoImmuntech plans to expand the application area of NT-I7 through partnerships while focusing its capabilities on…...
LEO Pharma acquires dermatology drug for 435 million USD
8+ hour, 47+ min ago (84+ words) Here you can administrate your corporate solutions users. Welcome to our Corporate client solution Your IP is registered with the company mentioned above and provides access to Life Science Nordic. Danish pharmaceutical company LEO Pharma has made an acquisition of…...
ROST 260814 180.00P (ROST260814P180000) Stock Options Chain | Quotes & News
1+ week, 3+ hour ago (10+ words) Moomoo...
CCCC celebrates opening of E. Eugene Moore Center biotech facility
1+ hour, 10+ min ago (13+ words) The Sanford Herald...
Antengene Presents Key R&D Highlights at the Evercore 2nd China Biotech Summit | AAP
1+ hour, 46+ min ago (1106+ words) Antengene Presents Key R&D Highlights at the Evercore 2nd China Biotech Summit aap.com.au Antengene Presents Key R&D Highlights at the Evercore 2nd China Biotech Summit SHANGHAI and HONG KONG, Aug. 19, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a…...
GenScript Reports 27.3% First-Half 2026 Revenue Growth as AI Drug Discovery Business Doubles | AAP
59+ min ago (131+ words) Adjusted net profit surges 203.3% as Gene-to-Protein generates two-thirds of GenScript Life Science Group revenue The AI-enabled drug discovery business doubled year over year and maintained rapid growth for a third consecutive half-year reporting period, driven by demand from AI-focused biotechnology…...